TrialESMO open2020

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503).

Satoru Iwasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.